Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
Sponsor: Intra-Cellular Therapies, Inc.
Summary
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.
Official title: A Phase 1b, Open-label Study to Determine the Pharmacokinetics, Safety, and Tolerability of Single, Ascending Doses of Lumateperone Long-acting Injectable Formulations Administered Intramuscularly to Patients With Schizophrenia or Schizoaffective Disorder
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2024-08-23
Completion Date
2025-11-20
Last Updated
2026-06-26
Healthy Volunteers
No
Conditions
Interventions
Lumateperone Capsule
Lumateperone 42 mg capsule, oral administration
Lumateperone LAI
Lumateperone LAI X500-E2 IM injection
Lumateperone LAI
Lumateperone LAI X500-E3 IM injection
Lumateperone LAI
Lumateperone LAI X500-X2 IM injection
Lumateperone LAI
Lumateperone LAI X500-X5 IM injection
Lumateperone LAI
Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
Locations (4)
Clinical Site 2
Los Alamitos, California, United States
Clinical Site 3
Atlanta, Georgia, United States
Clinical Site 4
Decatur, Georgia, United States
Clinical Site 1
Marlton, New Jersey, United States